published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable death D28detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Aman, 2021 0.51 [0.27; 0.96] Bennett-Guerrero, 2021 0.86 [0.24; 3.11] CAN-COVID, 2020 0.67 [0.30; 1.50] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] Gunst JD, 2021 0.99 [0.29; 3.42] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Lanzoni, 2021 0.14 [0.02; 0.96] Metcovid, 2020 0.92 [0.67; 1.28] Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Shi, 2020 0.53 [0.01; 27.55] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Tang X, 2020 0.98 [0.93; 1.02] University of Minnesota, 2020 1.29 [0.51; 3.26] Zhang, 2020 0.50 [0.17; 1.50] 0.77[0.68; 0.88]ACTT-2 (Kalil), 2020, Aman, 2021, Bennett-Guerrero, 2021, CAN-COVID, 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lanzoni, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, NCT04412772 (ARCHITECTS), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tang X, 2020, University of Minnesota, 2020, Zhang, 20202942%12,834moderatecritical death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] Gunst JD, 2021 0.55 [0.26; 1.17] Lopardo, 2021 0.65 [0.35; 1.22] 0.72[0.48; 1.06]BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, Lopardo, 202130%688moderatenot evaluable deathsdetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21] ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Aman, 2021 0.51 [0.27; 0.96] BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CAN-COVID, 2020 0.67 [0.30; 1.50] CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] CAPE-COVID, 2020 0.45 [0.20; 1.02] CCAP-2, 2021 2.03 [0.61; 6.77] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] EMPACTA, 2020 1.13 [0.54; 2.40] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gonzalez (HCQ), 2020 0.33 [0.06; 1.78] Gonzalez (IVER), 2020 0.83 [0.23; 3.02] Gunst JD, 2021 0.70 [0.20; 2.49] HYCOVID, 2020 0.54 [0.21; 1.40] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Kirti, 2021 0.12 [0.01; 2.36] Lanzoni, 2021 0.11 [0.01; 0.93] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] Libster, 2020 0.50 [0.09; 2.71] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] Lopardo, 2021 0.57 [0.24; 1.37] Metcovid, 2020 0.92 [0.67; 1.28] Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67] Murai, 2020 1.53 [0.53; 4.43] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04442191, 2021 0.11 [0.00; 143.68] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] ORCHID, 2020 1.07 [0.54; 2.11] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] ProPAC-COVID, 2021 0.08 [0.00; 8.65] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Salehzadeh, 2020 1.00 [0.02; 51.41] SAVE-MORE, 2021 0.45 [0.20; 0.99] Shi, 2020 0.53 [0.01; 27.55] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Synairgen SG016, 2020 0.16 [0.01; 3.31] Tang X, 2020 0.98 [0.93; 1.02] TEACH, 2020 1.07 [0.34; 3.37] University of Minnesota, 2020 0.68 [0.11; 4.16] Zhang, 2020 0.50 [0.17; 1.50] 0.78[0.70; 0.87]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, Aman, 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CCAP-2, 2021, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, Gunst JD, 2021, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirti, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04412772 (ARCHITECTS), 0, NCT04442191, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, ProPAC-COVID, 2021, Rosas (REMDACTA), 2021, Salehzadeh, 2020, SAVE-MORE, 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, University of Minnesota, 2020, Zhang, 20205532%19,908moderatecritical deaths (time to event analysis only)detailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] COV-BARRIER, 2021 0.57 [0.41; 0.79] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gunst JD, 2021 0.70 [0.20; 2.49] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Lanzoni, 2021 0.11 [0.01; 0.93] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Zhang, 2020 0.50 [0.17; 1.50] 0.74[0.62; 0.87]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, COV-BARRIER, 2021, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, PlasmAr, 2020, Rosas (REMDACTA), 2021, Zhang, 20201727%9,200moderatelow clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] CONTAIN COVID-19, 2021 0.94 [0.75; 1.18] COV-BARRIER, 2021 1.12 [0.58; 2.16] EMPACTA, 2020 0.55 [0.33; 0.92] Libster, 2020 0.52 [0.29; 0.94] SAVE-MORE, 2021 0.36 [0.26; 0.50] STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07] Synairgen SG016, 2020 0.50 [0.18; 1.38] Tang X, 2020 1.00 [0.13; 7.45] TEACH, 2020 1.80 [0.62; 5.21] Zhang, 2020 0.40 [0.10; 1.65] 0.71[0.52; 0.96]BACC Bay Tocilizumab Trial, 2020, CAP-China (Wang et al.), 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, EMPACTA, 2020, Libster, 2020, SAVE-MORE, 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Zhang, 20201268%3,476lowlow clinical improvementdetailed resultsACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20] ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] Bennett-Guerrero, 2021 0.75 [0.21; 2.68] CAN-COVID, 2020 1.39 [0.76; 2.54] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] COV-BARRIER, 2021 1.25 [1.04; 1.50] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] EMPACTA, 2020 1.15 [0.90; 1.47] Gunst JD, 2021 1.14 [0.83; 1.57] ITAC, 2022 1.06 [0.77; 1.45] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lopardo, 2021 1.61 [0.75; 3.49] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 1.02 [0.73; 1.42] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] Synairgen SG016, 2020 2.32 [1.07; 5.04] Tang X, 2020 1.04 [0.67; 1.62] 1.13[1.07; 1.19]ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Gunst JD, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020245%10,285moderatelow clinical improvement (14-day)detailed resultsACTT-2 (Kalil), 2020 1.30 [1.03; 1.64] CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] COV-BARRIER, 2021 1.28 [1.05; 1.56] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] Kalil (ACTT-3), 2021 1.01 [0.79; 1.29] ORCHID, 2020 1.02 [0.73; 1.42] Tang X, 2020 1.33 [0.57; 3.11] 1.20[1.07; 1.34]ACTT-2 (Kalil), 2020, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, ORCHID, 2020, Tang X, 202070%4,429lownot evaluable clinical improvement (28-day)detailed resultsBennett-Guerrero, 2021 1.02 [0.25; 4.20] CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76] ORCHID, 2020 0.97 [0.69; 1.37] O’Donnell, 2021 1.38 [0.73; 2.61] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] Synairgen SG016, 2020 3.15 [1.39; 7.14] 1.30[1.10; 1.52]Bennett-Guerrero, 2021, CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020101%2,739moderatelow clinical improvement (7-day)detailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] ITAC, 2022 1.06 [0.77; 1.45] Kirti, 2021 0.90 [0.77; 1.06] ORCHID, 2020 1.16 [0.84; 1.61] 0.95[0.84; 1.08]ACTIV-3/TICO LY-CoV555 , 2020, CAP-China (Wang et al.), 2020, ITAC, 2022, Kirti, 2021, ORCHID, 202050%1,726moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] Bennett-Guerrero, 2021 0.75 [0.21; 2.68] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] EMPACTA, 2020 1.15 [0.90; 1.47] Gunst JD, 2021 1.14 [0.83; 1.57] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 0.97 [0.69; 1.36] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] Shinkai, 2021 1.40 [0.91; 2.15] Tang X, 2020 1.04 [0.67; 1.62] 1.12[1.06; 1.19]ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, CAP-China (Wang et al.), 2020, EMPACTA, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Shinkai, 2021, Tang X, 2020150%5,581moderatelow death or ventilationdetailed resultsACTT-2 (Kalil), 2020 0.69 [0.50; 0.95] BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CAPE-COVID, 2020 0.71 [0.37; 1.35] EMPACTA, 2020 0.56 [0.32; 0.97] Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] Gonzalez (HCQ), 2020 0.69 [0.22; 2.21] Gonzalez (IVER), 2020 0.89 [0.30; 2.64] HYCOVID, 2020 1.12 [0.45; 2.79] LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] ORCHID, 2020 1.13 [0.60; 2.13] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97] Synairgen SG016, 2020 0.38 [0.09; 1.63] 0.73[0.64; 0.84]ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, ORCHID, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020140%4,614moderatelow hospital dischargedetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20] CAPE-COVID, 2020 1.67 [0.87; 3.19] EMPACTA, 2020 1.16 [0.90; 1.49] Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] Gonzalez (HCQ), 2020 1.38 [0.46; 4.16] Gonzalez (IVER), 2020 0.71 [0.15; 3.40] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] Kirti, 2021 1.20 [0.73; 1.98] Murai, 2020 0.99 [0.71; 1.38] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] Synairgen SG016, 2020 1.63 [0.61; 4.35] University of Minnesota, 2020 0.64 [0.37; 1.11] 1.06[0.96; 1.18]ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Murai, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, University of Minnesota, 2020133%3,512moderatelow hospitalizationdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] University of Minnesota, 2020 1.63 [0.94; 2.85] 1.58[0.92; 2.70]Jagannathan, 2020, University of Minnesota, 202020%325moderatenot evaluable mechanical ventilationdetailed resultsACTT-2 (Kalil), 2020 0.64 [0.44; 0.93] CAPE-COVID, 2020 0.95 [0.44; 2.04] COVACTA (Rosas), 2020 0.67 [0.39; 1.14] Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] Gunst JD, 2021 2.27 [0.62; 8.26] Kirti, 2021 0.20 [0.00; 8.69] Metcovid, 2020 1.19 [0.56; 2.49] Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19] Murai, 2020 0.49 [0.21; 1.14] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] SAVE-MORE, 2021 0.47 [0.03; 7.48] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] University of Minnesota, 2020 1.34 [0.66; 2.73] 0.87[0.68; 1.12]ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Kirti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, O’Donnell, 2021, PlasmAr, 2020, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, University of Minnesota, 20201518%4,846moderatelow mechanical ventilation (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] Gunst JD, 2021 0.69 [0.14; 3.42] 0.77[0.31; 1.90]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 202120%396moderatenot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Jagannathan, 2020 0.81 [0.56; 1.18] Tang X, 2020 1.78 [1.06; 3.00] 1.03[0.73; 1.47]Chaccour, 2020, Jagannathan, 2020, Tang X, 2020369%230moderatenot evaluable viral clearance (time to event analysis only)detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] Tang X, 2020 1.78 [1.06; 3.00] 1.18[0.54; 2.54]Jagannathan, 2020, Tang X, 2020283%206moderatenot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] 0.91[0.77; 1.08]Chaccour, 2020, Kirti, 202120%136lownot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] Gunst JD, 2021 0.80 [0.34; 1.90] Kirti, 2021 0.90 [0.30; 2.70] Libster, 2020 0.33 [0.07; 1.58] Lopardo, 2021 0.67 [0.35; 1.28] Murai, 2020 0.71 [0.37; 1.37] ProPAC-COVID, 2021 1.24 [0.26; 5.80] Tang X, 2020 1.00 [0.13; 7.45] 0.66[0.49; 0.91]COVACTA (Rosas), 2020, Gunst JD, 2021, Kirti, 2021, Libster, 2020, Lopardo, 2021, Murai, 2020, ProPAC-COVID, 2021, Tang X, 202080%1,349moderatenot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable recoverydetailed resultsACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32] ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37] ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46] COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94] Gunst JD, 2021 1.18 [0.87; 1.61] Lanzoni, 2021 3.46 [1.05; 11.35] Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05] Synairgen SG016, 2020 2.19 [1.03; 4.67] 1.10[0.97; 1.26]ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020942%2,636lowserious AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable composite safety outcome detailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11] 1.56[0.78; 3.11]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] CAN-COVID, 2020 0.73 [0.45; 1.19] CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Gunst JD, 2021 1.84 [0.79; 4.30] ITAC, 2022 0.98 [0.66; 1.46] Jagannathan, 2020 1.00 [0.14; 7.34] Lanzoni, 2021 0.10 [0.01; 0.69] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Murai, 2020 0.99 [0.02; 50.39] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] ORCHID, 2020 1.26 [0.56; 2.84] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Shi, 2020 1.08 [0.04; 32.96] Shinkai, 2021 2.80 [0.14; 56.95] 0.90[0.77; 1.05]BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COVACTA (Rosas), 2020, Gunst JD, 2021, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 20211816%6,020moderatelow superinfectiondetailed resultsACTT-2 (Kalil), 2020 0.50 [0.32; 0.79] CAPE-COVID, 2020 0.81 [0.49; 1.34] Metcovid, 2020 0.98 [0.65; 1.47] 0.74[0.49; 1.11]ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020357%1,575lownot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] COVACTA (Rosas), 2020 0.87 [0.52; 1.45] Gunst JD, 2021 0.80 [0.43; 1.51] Jagannathan, 2020 1.33 [0.63; 2.78] Lanzoni, 2021 0.18 [0.02; 1.95] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Murai, 2020 1.99 [0.07; 59.94] ORCHID, 2020 1.42 [0.87; 2.34] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Shi, 2020 0.88 [0.38; 2.03] Shinkai, 2021 19.54 [7.77; 49.11] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] TEACH, 2020 1.16 [0.55; 2.42] 1.24[0.85; 1.82]Chaccour, 2020, COVACTA (Rosas), 2020, Gunst JD, 2021, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, ORCHID, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, TEACH, 20201570%3,080moderatelow deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296lownot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-06 12:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290